GSK patented the adjuvant and took control of the supply of the ingredients in it.

Source: https://www.propublica.org/article/how-big-pharma-company-stalled-tuberculosis-vaccine-to-pursue-bigger-profits

It’s not been well characterized in this context, as you know, it’s been well characterized, in the adjuvant setting identifying patients at high risk of disease recurrence.

Source: https://seekingalpha.com/article/4586315-gritstone-bio-inc-grts-q4-2022-results-earnings-call-transcript?source=feed_all_articles

Pneumonitis occurred in 7% (41/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions.

Source: https://investingnews.com/preclinical-data-shows-arg-007-inhibits-one-of-the-main-causes-of-alzheimers-disease/